Cargando…

Evaluation of the prophylaxis and treatment of COVID-associated coagulopathy

Most of the current “literature” surrounding the presence of thrombosis in COVID-19 disease and appropriate prophylaxis/treatment modalities is certainly retrospective at best, and anecdotal at worst. But in these times of rapidly changing information and perspective, an assessment of all available...

Descripción completa

Detalles Bibliográficos
Autores principales: Elbeddini, Ali, Gerochi, Rachel, Elshahawi, Ahmed
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7586671/
https://www.ncbi.nlm.nih.gov/pubmed/33117545
http://dx.doi.org/10.1186/s40545-020-00274-8
_version_ 1783600046794604544
author Elbeddini, Ali
Gerochi, Rachel
Elshahawi, Ahmed
author_facet Elbeddini, Ali
Gerochi, Rachel
Elshahawi, Ahmed
author_sort Elbeddini, Ali
collection PubMed
description Most of the current “literature” surrounding the presence of thrombosis in COVID-19 disease and appropriate prophylaxis/treatment modalities is certainly retrospective at best, and anecdotal at worst. But in these times of rapidly changing information and perspective, an assessment of all available data (including expert opinion) is the goal of this review. Bleeding risk factors for COVID-19-associated bleeding may include other systemic diseases, including hypertension, diabetes, cardiovascular disease, and immunosuppression. Individuals with hypertension should not discontinue their medication. Current evidence does not support changes in the management of hypertension. As COVID-19 progresses, coagulation pathways are activated as part of the host inflammatory response to limit the viral infection. Specifically, D-dimers, products of fibrin as it is degraded within clots, are elevated in many cases of hospitalized COVID-19 patients. D-dimers are an indicator of a clot (thrombus) formation and breakdown. More severe COVID-19 disease may lead to overt disseminated intravascular coagulation (DIC), associated with high mortality. DIC is a coagulopathy that may arise from the systemic inflammatory response to the virus and damaged tissue caused by the infection. Bleeding risk factors may include other systemic diseases, including hypertension, diabetes, cardiovascular disease, and immunosuppression. Individuals with hypertension should not discontinue their medication. Current evidence does not support changes in the management of hypertension. As COVID-19 progresses, coagulation pathways are activated as part of the host inflammatory response to limit the viral infection. Specifically, D-dimers, products of fibrin as it is degraded within clots, are elevated in many cases of hospitalized COVID-19 patients. D-dimers are an indicator of a clot (thrombus) formation and breakdown. More severe COVID-19 disease may lead to overt disseminated intravascular coagulation (DIC), associated with high mortality. DIC is a coagulopathy that may arise from the systemic inflammatory response to the virus and damaged tissue caused by the infection. My manuscript presents the risk and evidence around the COVID-19-associated coagulopathies
format Online
Article
Text
id pubmed-7586671
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-75866712020-10-27 Evaluation of the prophylaxis and treatment of COVID-associated coagulopathy Elbeddini, Ali Gerochi, Rachel Elshahawi, Ahmed J Pharm Policy Pract Commentary Most of the current “literature” surrounding the presence of thrombosis in COVID-19 disease and appropriate prophylaxis/treatment modalities is certainly retrospective at best, and anecdotal at worst. But in these times of rapidly changing information and perspective, an assessment of all available data (including expert opinion) is the goal of this review. Bleeding risk factors for COVID-19-associated bleeding may include other systemic diseases, including hypertension, diabetes, cardiovascular disease, and immunosuppression. Individuals with hypertension should not discontinue their medication. Current evidence does not support changes in the management of hypertension. As COVID-19 progresses, coagulation pathways are activated as part of the host inflammatory response to limit the viral infection. Specifically, D-dimers, products of fibrin as it is degraded within clots, are elevated in many cases of hospitalized COVID-19 patients. D-dimers are an indicator of a clot (thrombus) formation and breakdown. More severe COVID-19 disease may lead to overt disseminated intravascular coagulation (DIC), associated with high mortality. DIC is a coagulopathy that may arise from the systemic inflammatory response to the virus and damaged tissue caused by the infection. Bleeding risk factors may include other systemic diseases, including hypertension, diabetes, cardiovascular disease, and immunosuppression. Individuals with hypertension should not discontinue their medication. Current evidence does not support changes in the management of hypertension. As COVID-19 progresses, coagulation pathways are activated as part of the host inflammatory response to limit the viral infection. Specifically, D-dimers, products of fibrin as it is degraded within clots, are elevated in many cases of hospitalized COVID-19 patients. D-dimers are an indicator of a clot (thrombus) formation and breakdown. More severe COVID-19 disease may lead to overt disseminated intravascular coagulation (DIC), associated with high mortality. DIC is a coagulopathy that may arise from the systemic inflammatory response to the virus and damaged tissue caused by the infection. My manuscript presents the risk and evidence around the COVID-19-associated coagulopathies BioMed Central 2020-10-26 /pmc/articles/PMC7586671/ /pubmed/33117545 http://dx.doi.org/10.1186/s40545-020-00274-8 Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Commentary
Elbeddini, Ali
Gerochi, Rachel
Elshahawi, Ahmed
Evaluation of the prophylaxis and treatment of COVID-associated coagulopathy
title Evaluation of the prophylaxis and treatment of COVID-associated coagulopathy
title_full Evaluation of the prophylaxis and treatment of COVID-associated coagulopathy
title_fullStr Evaluation of the prophylaxis and treatment of COVID-associated coagulopathy
title_full_unstemmed Evaluation of the prophylaxis and treatment of COVID-associated coagulopathy
title_short Evaluation of the prophylaxis and treatment of COVID-associated coagulopathy
title_sort evaluation of the prophylaxis and treatment of covid-associated coagulopathy
topic Commentary
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7586671/
https://www.ncbi.nlm.nih.gov/pubmed/33117545
http://dx.doi.org/10.1186/s40545-020-00274-8
work_keys_str_mv AT elbeddiniali evaluationoftheprophylaxisandtreatmentofcovidassociatedcoagulopathy
AT gerochirachel evaluationoftheprophylaxisandtreatmentofcovidassociatedcoagulopathy
AT elshahawiahmed evaluationoftheprophylaxisandtreatmentofcovidassociatedcoagulopathy